TransCode Therapeutics Inc Stock

$0.34

2.92% yesterday

Nasdaq, Nov 15, 10:17 pm CET

ISIN

US89357L1052

Symbol

RNAZ

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

TransCode Therapeutics Inc Stock price

$0.34

-3,199.66 99.99% 5Y

Nasdaq, Closing price Fri, Nov 15 2024

-0.01 2.92%

ISIN

US89357L1052

Symbol

RNAZ

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$5.87m
Enterprise Value	$2.75m
P/E (TTM) P/E ratio	0.00
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	1.87
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-17.79m
Free Cash Flow (TTM) Free Cash Flow	$-15.32m
Cash position	$3.35m
EPS (TTM) EPS	$-75.05
P/E forward	negative
P/S forward	12.08
EV/Sales forward	5.84
Short interest	4.31%

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Get Started for Free Today

TransCode Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

1 Analyst has issued a forecast TransCode Therapeutics Inc:

1x Buy

100%

More details on Analyst Estimates Including Price Targets

1 Analyst has issued a forecast TransCode Therapeutics Inc:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from TransCode Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '24		+/- %
Revenue	- -	- 100%
- Direct Costs	0.56 0.56	93% 93% -
Gross Profit	-0.56 -0.56	93% 93% -
- Selling and Administrative Expenses	5.15 5.15	41% 41% -
- Research and Development Expense	12 12	2% 2% -
EBITDA	-17 -17	15% 15% -
- Depreciation and Amortization	0.56 0.56	93% 93% -
EBIT (Operating Income) EBIT	-18 -18	13% 13% -
Net Profit	-18 -18	4% 4% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

TransCode Therapeutics Inc Stock News

Neutral

GlobeNewsWire

●

11 days ago

TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance

BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has received notice from The Nasdaq Stock Market LLC (Nasdaq) that the Nasdaq Hearings Panel before which TransCode appeared on October 1, 2024, has determined to grant TransCode's request to...

Neutral

GlobeNewsWire

●

about 2 months ago

TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate

Two patients dosed; several additional patients screened for enrollment Trial to evaluate safety and tolerability of TTX-MC138 in patients with metastatic cancer TTX-MC138 is an antisense oligonucleotide conjugated to TransCode's proprietary TTX delivery system designed to inhibit microRNA-10b, a known driver of metastasis in multiple cancers Phase 1 clinical trial follows evidence of delivery ...

Neutral

GlobeNewsWire

●

2 months ago

TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate

BOSTON, Sept. 05, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has been awarded a $2 million Direct to Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to support clinical evaluation of TTX-MC138, Tra...

More TransCode Therapeutics Inc News

Company Profile

TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.

Head office	United States
CEO	Thomas Fitzgerald
Employees	10
Founded	2016
Website	www.transcodetherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now